{"id":684669,"date":"2022-09-13T09:08:34","date_gmt":"2022-09-13T13:08:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\/"},"modified":"2022-09-13T09:08:34","modified_gmt":"2022-09-13T13:08:34","slug":"eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\/","title":{"rendered":"Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution"},"content":{"rendered":"
\n

— Expected to be accretive to 2023 earnings —<\/p>\n

DEER PARK, Ill., Sept. 13, 2022 (GLOBE NEWSWIRE) — Eton Pharmaceuticals (\u201cEton\u201d or \u201cthe Company\u201d) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the acquisition of betaine anhydrous for oral solution.<\/p>\n

“We are excited to add another FDA-approved rare disease product to our growing metabolic genetics portfolio. Betaine shares the same prescriber base as our carglumic acid tablets, so it is an attractive opportunity to leverage our existing commercial infrastructure. We plan to integrate the product later this year and expect the transaction to be accretive to 2023 earnings,\u201d said Sean Brynjelsen, CEO of Eton Pharmaceuticals. \u201cThis acquisition allows us to further advance our mission of commercializing products for small, underserved orphan populations, and we will continue to seek out attractive late-stage rare disease products to expand our portfolio.\u201d<\/p>\n

Betaine anhydrous for oral solution targets a population of fewer than 2,000 patients in the United States, with an estimated market of $10 million annually.<\/p>\n

\n About Eton Pharmaceuticals<\/strong>
\n
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases. The Company currently commercializes ALKINDI SPRINKLE\u00ae and Carglumic Acid tablets and has four additional rare disease products under development, including dehydrated alcohol injection and the ZENEO\u00ae hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com<\/a>.<\/p>\n

\n Investor Relations:<\/strong>
\n
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com<\/a><\/p>\n

Source: Eton Pharmaceuticals<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

— Expected to be accretive to 2023 earnings — DEER PARK, Ill., Sept. 13, 2022 (GLOBE NEWSWIRE) — Eton Pharmaceuticals (\u201cEton\u201d or \u201cthe Company\u201d) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the acquisition of betaine anhydrous for oral solution. “We are excited to add another FDA-approved rare disease product to our growing metabolic genetics portfolio. Betaine shares the same prescriber base as our carglumic acid tablets, so it is an attractive opportunity to leverage our existing commercial infrastructure. We plan to integrate the product later this year and expect the transaction to be accretive to 2023 earnings,\u201d said Sean Brynjelsen, CEO of Eton Pharmaceuticals. \u201cThis acquisition allows us to further … <\/p>\n

Continue reading “Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-684669","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"— Expected to be accretive to 2023 earnings — DEER PARK, Ill., Sept. 13, 2022 (GLOBE NEWSWIRE) — Eton Pharmaceuticals (\u201cEton\u201d or \u201cthe Company\u201d) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the acquisition of betaine anhydrous for oral solution. “We are excited to add another FDA-approved rare disease product to our growing metabolic genetics portfolio. Betaine shares the same prescriber base as our carglumic acid tablets, so it is an attractive opportunity to leverage our existing commercial infrastructure. We plan to integrate the product later this year and expect the transaction to be accretive to 2023 earnings,\u201d said Sean Brynjelsen, CEO of Eton Pharmaceuticals. \u201cThis acquisition allows us to further … Continue reading "Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-13T13:08:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NTYzNSM1MTQ5MTc5IzIxMjI5ODQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution\",\"datePublished\":\"2022-09-13T13:08:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\\\/\"},\"wordCount\":258,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NTYzNSM1MTQ5MTc5IzIxMjI5ODQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\\\/\",\"name\":\"Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NTYzNSM1MTQ5MTc5IzIxMjI5ODQ=\",\"datePublished\":\"2022-09-13T13:08:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NTYzNSM1MTQ5MTc5IzIxMjI5ODQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NTYzNSM1MTQ5MTc5IzIxMjI5ODQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\/","og_locale":"en_US","og_type":"article","og_title":"Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution - Market Newsdesk","og_description":"— Expected to be accretive to 2023 earnings — DEER PARK, Ill., Sept. 13, 2022 (GLOBE NEWSWIRE) — Eton Pharmaceuticals (\u201cEton\u201d or \u201cthe Company\u201d) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the acquisition of betaine anhydrous for oral solution. “We are excited to add another FDA-approved rare disease product to our growing metabolic genetics portfolio. Betaine shares the same prescriber base as our carglumic acid tablets, so it is an attractive opportunity to leverage our existing commercial infrastructure. We plan to integrate the product later this year and expect the transaction to be accretive to 2023 earnings,\u201d said Sean Brynjelsen, CEO of Eton Pharmaceuticals. \u201cThis acquisition allows us to further … Continue reading \"Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-13T13:08:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NTYzNSM1MTQ5MTc5IzIxMjI5ODQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution","datePublished":"2022-09-13T13:08:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\/"},"wordCount":258,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NTYzNSM1MTQ5MTc5IzIxMjI5ODQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\/","name":"Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NTYzNSM1MTQ5MTc5IzIxMjI5ODQ=","datePublished":"2022-09-13T13:08:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NTYzNSM1MTQ5MTc5IzIxMjI5ODQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NTYzNSM1MTQ5MTc5IzIxMjI5ODQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-anhydrous-for-oral-solution\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/684669","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=684669"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/684669\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=684669"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=684669"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=684669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}